Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic

L.B. Hough, J.W. Nalwalk, J. Yang, J.L. Conroy, M.A. VanAlstine, W. Yang, J. Gargano, Z. Shan, S.Z. Zhang, M.P. Wentland, J.G. Phillips, B.I. Knapp, J.M. Bidlack, O.P. Zuiderveld, R. Leurs, X. Ding

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

The search for the mechanism of action of improgan (a nonopioid analgesic) led to the recent discovery of CC12, a compound that blocks improgan antinociception. Because CC12 is a cytochrome P450 inhibitor, and brain P450 mechanisms were recently shown to be required in opioid analgesic signaling, pharmacological and transgenic studies were performed in rodents to test the hypothesis that improgan antinociception requires brain P450 epoxygenase activity. Intracerebroventricular (ICV) administration of the P450 inhibitors miconazole and fluconazole, and the arachidonic acid (AA) epoxygenase inhibitor N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH) potently inhibited improgan antinociception in rats at doses that were inactive alone. MW06-25, a new P450 inhibitor that combines chemical features of CC12 and miconazole, also potently blocked improgan antinociception. Although miconazole and CC12 were weakly active at opioid and histamine H
Original languageEnglish
Pages (from-to)878
JournalPain
Volume152
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic'. Together they form a unique fingerprint.

Cite this